Get all premium features to the best stock analysis tool

Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused ​sales in outpatient settings to fall sharply, its finance chief ‌told Reuters on Tuesday.

Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion Kerecis impairment and currency headwinds. Management guides for 5–6% organic revenue growth and 5% EBIT growth in FY25/26, but targets 7–8% annual organic growth and 20%+ ROIC by FY29/30.